The insider sales are too small to be informative. Focus on the upcoming PDUFA catalysts: Afrezza pediatric decision on May 29 (potential new patient population) and Furoscix ReadyFlow Autoinjector on July 26 (first IV-equivalent diuretic autoinjector). Q1 revenue growth of 15% and $134M cash position provide runway. Monitor for any insider buying ahead of these catalysts.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.28entry
- T+1 · 6mo ago −2.13%α −2.71% · $3.21
- T+5 · 6mo ago −9.76%α −9.16% · $2.96
- T+20 · 5mo ago +10.67%α +12.40% · $3.63
- T+60 · 3mo ago +18.60%α +14.21% · $3.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at MannKind Corp made open-market sales totaling $66K (0.007% of market cap) on May 12, 2026, one week after the company reported Q1 2026 revenue of $90.2M (+15% YoY) and highlighted upcoming PDUFA dates for Afrezza pediatric (May 29) and Furoscix ReadyFlow Autoinjector (July 26). The sales are trivial relative to the $1.0B market cap and are dwarfed by the $215K in tax-withholding share surrenders by the CEO and other executives on May 11, indicating the open-market sales are likely liquidity-driven rather than signaling a bearish view.
Key Financial Metrics
Key Facts
- Open-market sales: EVP Thomson sold $10K, Director Binder sold $56K, total $66K, or 0.007% of $1.0B market cap
- Tax-withholding share surrenders on May 11: CEO Castagna ($123K), EVP Thomson ($44K), Director Binder ($20K), CPWO Tross ($28K), total $215K, non-cash events
- Q1 2026 revenue $90.2M (+15% YoY); Afrezza $15.3M (+3%), Furoscix $15.5M (new), royalties $32.7M (+9%)
- Two upcoming PDUFA dates: Afrezza pediatric (May 29, 2026) and Furoscix ReadyFlow Autoinjector (July 26, 2026)
- Cash and investments $134M as of March 31, 2026; $36.3M convertible notes settled for $35.5M cash + 569K shares
Financial Impact
Open-market sales of $66K represent 0.007% of market cap, immaterial
Risk Factors
- Afrezza pediatric PDUFA denial on May 29 would remove a key growth catalyst
- Furoscix ReadyFlow Autoinjector PDUFA denial on July 26 would slow Furoscix growth trajectory
- Selling, general and administrative expenses rose 116% YoY to $54.1M, pressuring margins
- R&D expenses rose 56% to $17.2M, reflecting pipeline investment but near-term cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MNKD-1778718640742 |
Track record
17 reports on MNKD
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers